KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average (2016 - 2025)

Neogenomics (NEO) has disclosed Equity Average for 15 consecutive years, with $837.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 7.49% year-over-year to $837.4 million, compared with a TTM value of $837.4 million through Dec 2025, down 7.49%, and an annual FY2025 reading of $869.5 million, down 5.69% over the prior year.
  • Equity Average was $837.4 million for Q4 2025 at Neogenomics, down from $846.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.1 billion in Q3 2021 and bottomed at $769.0 million in Q1 2021.
  • Average Equity Average over 5 years is $959.1 million, with a median of $948.1 million recorded in 2023.
  • The sharpest move saw Equity Average soared 73.07% in 2021, then fell 10.44% in 2022.
  • Year by year, Equity Average stood at $1.1 billion in 2021, then fell by 10.44% to $1.0 billion in 2022, then dropped by 6.07% to $944.5 million in 2023, then decreased by 4.15% to $905.3 million in 2024, then decreased by 7.49% to $837.4 million in 2025.
  • Business Quant data shows Equity Average for NEO at $837.4 million in Q4 2025, $846.2 million in Q3 2025, and $871.2 million in Q2 2025.